Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
Stress such as high oxygen or inflammation can result in damage to proteins by processes such as oxidation or alternative regulation of signaling pathways by post-translational modification of proteins (e.g., phosphorylation). Delivery of oxygen in high concentrations to the lungs can result in damage, which is mediated in large part by reactive oxygen species. Inflammation can result in activation of intracellular signaling pathways. This study will evaluate modification of proteins and nucleic acids in bronchoalveolar lavage fluid, bronchial epithelial cells, and peripheral blood of indiv...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • History - good overall health without history of recent (within 3 months) acute disease;
- • Physical examination within normal limits;
- • Laboratory evaluation; including complete blood count (CBC), serum electrolyte determinations, clotting times, chest x-ray, pulmonary function testing, and an electrocardiogram (EKG) - within normal limits;
- • Non-smokers defined as having never smoked or not smoked in the past 2 years;
- • Smokers defined as moderate (1 pack per day for 3+ years) or heavy (1-2 packs for 10+ years);
- • Subjects must be willing to make the time commitment necessary for the study.
- EXCLUSION CRITERIA:
- • Any study subject who does not fulfill the criteria for eligibility.
- • Individuals with a history of allergy or adverse reactions to atropine or any local anesthetic;
- • Individuals testing positive for the human immunodeficiency virus or hepatitis virus;
- • Individuals on chronic medications or currently receiving medications;
- • Pregnant or lactating individuals, since the effects of hyperoxia on the fetus are unclear.
Trial Officials
Joel Moss, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials